LifeCare Partners

KUPANDO is an innovative biopharmaceutical company focused on developing TLR 4/7 agonists to enhance innate immunity. The company aims to deliver safe and affordable immunotherapy options for cancer patients, while also creating immunostimulatory drugs designed to prevent infectious diseases. KUPANDO's research targets toll-like receptors that play a crucial role in identifying cancer and infection markers, which subsequently activate the innate immune system. By concentrating on these mechanisms, KUPANDO seeks to provide effective treatment solutions for both cancer and infectious diseases, making significant strides in the field of immunotherapy.

B-rayZ is a company that originated as a spin-off from the University Hospital Zurich, focusing on the intersection of artificial intelligence and medical imaging. Comprising a team of professional radiologists, data scientists, and physicians with extensive experience in radiology, B-rayZ specializes in developing predictive deep learning analytical tools and algorithms. Their software is designed to assist radiologists specifically in the area of mammography, providing real-time assessments of image quality and breast density. This technology facilitates accurate and standardized evaluations of medical imaging data, ultimately enhancing breast cancer detectability. By equipping specialists with intelligent tools, B-rayZ aims to improve the detection of breast cancer while also contributing to the reduction of healthcare costs.

NeoPrediX specializes in developing decision support tools focused on maternal, neonatal, and perinatal care. The company creates innovative screening platforms that leverage intelligent algorithms and digital health solutions, supported by extensive medical data and scientific research. By translating complex medical information into actionable predictions, NeoPrediX aims to enhance clinical decision-making for healthcare professionals working in pediatrics. Their technology is designed to improve and personalize medical strategies for newborn care, ultimately helping to prevent long-term health complications. With a team of experienced scientists, pediatricians, and neonatologists, NeoPrediX is committed to advancing healthcare practices in early life.

Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company's pipeline includes three small molecule products. The lead program, IMU-838, is a selective immune modulator that blocks the enzyme DHODH, inhibiting the metabolism of activated immune cells and exhibiting antiviral effects. It is being developed for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, targets psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Additionally, IMU-856 aims to restore intestinal barrier function for diseases involving bowel barrier dysfunction.

Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company's pipeline includes three small molecule products. The lead program, IMU-838, is a selective immune modulator that blocks the enzyme DHODH, inhibiting the metabolism of activated immune cells and exhibiting antiviral effects. It is being developed for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, targets psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Additionally, IMU-856 aims to restore intestinal barrier function for diseases involving bowel barrier dysfunction.

Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company's pipeline includes three small molecule products. The lead program, IMU-838, is a selective immune modulator that blocks the enzyme DHODH, inhibiting the metabolism of activated immune cells and exhibiting antiviral effects. It is being developed for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, targets psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Additionally, IMU-856 aims to restore intestinal barrier function for diseases involving bowel barrier dysfunction.

Kuros Biosciences AG is a biopharmaceutical company based in Schlieren, Switzerland, dedicated to the discovery, development, and commercialization of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has developed a robust pipeline of biopharmaceuticals targeting chronic diseases. Its key products include Neuroseal, a novel biomaterial for dural sealing, and the MagnetOs family of bone graft substitutes used in orthopedic, spinal, and dental applications. MagnetOs is approved for use in the EU and the US, with further formulations under development for regulatory submission. Kuros also has a range of clinical-stage products, including KUR-111 and KUR-113, which have completed Phase II clinical trials for treating specific bone fractures. The company has engaged in significant clinical research, enrolling over 600 patients in multinational trials, generating promising data regarding safety and efficacy in various applications, particularly within orthobiologics.

Leon Nanodrugs is a specialized product development company focused on enhancing existing drug formulations through advanced nanotechnology. The company develops a pipeline of improved drug products aimed at increasing the bioavailability of poorly water-soluble medicines. Utilizing its proprietary MJR® Technology platform, Leon Nanodrugs creates both polymeric and crystalline nanoparticles, which provide significant differentiation and added benefits for patients. The company also offers services that support pre-clinical and clinical-stage formulations for clients’ new chemical entities or established branded drugs, facilitating access to next-generation nano-formulated therapies that aim to improve patient outcomes.

Leukocare is a biotechnology company focused on developing protein stabilizing technologies aimed at reducing systemic inflammation during cardiac surgery. The company leverages its expertise in formulation development alongside bioinformatics and artificial intelligence to create innovative solutions for biopharmaceuticals, viral vectors, vaccines, and biofunctionalized devices. By employing an antibody that reduces leukocyte activity in extracorporeal blood circuits, Leukocare enables patients to benefit from minimized inflammation during surgical procedures.